Skip to main
ALEC
ALEC logo

Alector Inc (ALEC) Stock Forecast & Price Target

Alector Inc (ALEC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 18%
Hold 9%
Sell 9%
Strong Sell 9%

Bulls say

Alector Inc. is making significant strides in its clinical trials, particularly with AL001 showing a 48% reduction in the rate of clinical progression, suggesting potential stabilization for patients with neurodegeneration. The firm’s therapeutic candidates, especially AL101, exhibit differentiated pharmacokinetics (PK) that may enhance patient compliance and reduce overall treatment costs, further strengthening its market position. With no approved disease-modifying agents currently available and a sizable patient population estimated at over 10,000 in the US and EU, Alector appears to be well-positioned to capture substantial market opportunities in treating neurodegenerative diseases.

Bears say

Alector Inc reported a net loss of $2 million, or $0.02 per share, for the fourth quarter of 2024, highlighting the company's ongoing financial challenges. The failure of the INVOKE-2 Phase 2 trial for AL002 to meet primary efficacy endpoints raises concerns regarding the viability of its neurodegenerative treatment pipeline, resulting in a significant drop of over 30% in share price during after-hours trading. Furthermore, the potential risks associated with the clinical failure of key therapies AL001 and AL002, as well as challenges in achieving regulatory approval and commercial revenue estimates, contribute to a negative outlook for the company's stock.

Alector Inc (ALEC) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 18% recommend Buy, 9% suggest Holding, 9% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alector Inc (ALEC) Forecast

Analysts have given Alector Inc (ALEC) a Buy based on their latest research and market trends.

According to 11 analysts, Alector Inc (ALEC) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alector Inc (ALEC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.